Talphera, Inc. (FRA:R5XA)

Market Cap	50.36M
Revenue (ttm)	23.86K
Net Income (ttm)	-10.56M
Shares Out	n/a
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	1.092
Previous Close	1.062
Day's Range	1.092 - 1.092
52-Week Range	0.296 - 1.240
Beta	n/a
RSI	49.58
Earnings Date	Mar 24, 2026

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated ...

• Industry: Pharmaceutical Preparations
• Founded: 2005
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: R5XA

Financial Performance

Financial numbers in USD